Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction

Detalles Bibliográficos
Autores principales: Lin, ChangDong, Li, Yue, Zhang, YueBin, Liu, ZhaoYuan, Mu, Xia, Gu, Chenjian, Liu, Jing, Li, Yutang, Li, GuoHui, Chen, JianFeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129692/
https://www.ncbi.nlm.nih.gov/pubmed/34006835
http://dx.doi.org/10.1038/s41392-021-00619-y
_version_ 1783694354523619328
author Lin, ChangDong
Li, Yue
Zhang, YueBin
Liu, ZhaoYuan
Mu, Xia
Gu, Chenjian
Liu, Jing
Li, Yutang
Li, GuoHui
Chen, JianFeng
author_facet Lin, ChangDong
Li, Yue
Zhang, YueBin
Liu, ZhaoYuan
Mu, Xia
Gu, Chenjian
Liu, Jing
Li, Yutang
Li, GuoHui
Chen, JianFeng
author_sort Lin, ChangDong
collection PubMed
description
format Online
Article
Text
id pubmed-8129692
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81296922021-05-18 Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction Lin, ChangDong Li, Yue Zhang, YueBin Liu, ZhaoYuan Mu, Xia Gu, Chenjian Liu, Jing Li, Yutang Li, GuoHui Chen, JianFeng Signal Transduct Target Ther Letter Nature Publishing Group UK 2021-05-18 /pmc/articles/PMC8129692/ /pubmed/34006835 http://dx.doi.org/10.1038/s41392-021-00619-y Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter
Lin, ChangDong
Li, Yue
Zhang, YueBin
Liu, ZhaoYuan
Mu, Xia
Gu, Chenjian
Liu, Jing
Li, Yutang
Li, GuoHui
Chen, JianFeng
Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title_full Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title_fullStr Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title_full_unstemmed Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title_short Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
title_sort ceftazidime is a potential drug to inhibit sars-cov-2 infection in vitro by blocking spike protein–ace2 interaction
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129692/
https://www.ncbi.nlm.nih.gov/pubmed/34006835
http://dx.doi.org/10.1038/s41392-021-00619-y
work_keys_str_mv AT linchangdong ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT liyue ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT zhangyuebin ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT liuzhaoyuan ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT muxia ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT guchenjian ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT liujing ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT liyutang ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT liguohui ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction
AT chenjianfeng ceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction

Ejemplares similares